Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.

Cell - 17 Feb 2012

Singh Anurag, Sweeney Michael F, Yu Min, Burger Alexa, Greninger Patricia, Benes Cyril, Haber Daniel A, Settleman Jeff

Abstract excerpt

Colon cancers frequently harbor KRAS mutations, yet only a subset of KRAS mutant colon cancer cell lines are dependent upon KRAS signaling for survival. In a screen for kinases that promote survival of KRAS-dependent colon cancer cells, we found that the TAK1 kinase (MAP3K7) is required for tumor cell viability. The induction of apoptosis by RNAi-mediated depletion or pharmacologic inhibition of TAK1 is linked to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenomatous Polyposis Coli Protein
Share to beta Catenin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Morphogenetic Proteins

Share to Colonic Neoplasms

Share to Germ-Free Life

Share to Neoplasm Transplantation

Share to Transplantation, Heterologous

Share to Wnt Signaling Pathway

Source

Open in PubMed Open full text

Identifiers

PMID: 22341439
DOI: 10.1016/j.cell.2011.12.033
PMCID: PMC3291475

Genes

KRAS
APC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.PMID 22341439Read ↗

LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.Semantic proximity Read ↗

Oncogenic Kras drives invasion and maintains metastases in colorectal cancer.Semantic proximity Read ↗

Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancerSemantic proximity Read ↗

A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal CancerSemantic proximity Read ↗

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.Semantic proximity Read ↗

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.Semantic proximity Read ↗

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.Semantic proximity Read ↗

Oncogenic mutations in intestinal adenomas regulate Bim-mediated apoptosis induced by TGF-βSemantic proximity Read ↗

Combined Mutation of Apc, Kras, and Tgfbr2 Effectively Drives Metastasis of Intestinal Cancer.Semantic proximity Read ↗

Basroparib overcomes acquired resistance to MEK inhibitors by inhibiting Wnt-mediated cancer stemness in KRAS-mutated colorectal cancerSemantic proximity Read ↗

Crucial Role of Oncogenic KRAS Mutations in Apoptosis and Autophagy Regulation: Therapeutic Implications.Semantic proximity Read ↗

Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.